Expected to comprehensive in early 2010.

5-HT3 antagonists like Granisetron tend to be initial choice therapies but have to be given orally or via injection. Related StoriesChemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patientsMultigene test performed on tumor can recognize breast cancer patients who can properly avoid chemotherapyMD Anderson study reveals why chemotherapy medications not effective for many pancreatic cancer patientsThe clinical trial, expected to comprehensive in early 2010, will evaluate the safety, pharmacokinetics and bioavailability of single doses of intranasal Granisetron compared with oral and intravenous formulations. Dr Stephen Barr, Managing Director and President of Almac Discovery, stated: ‘The initiation of this Phase I study with intranasal Granisetron is usually a significant further milestone for Almac Discovery.This significantly reduces Ack1 activity and slows tumor formation,’ Earp said. Furthermore, the team compared Ack1 activation in advanced prostate cancer cells from patients with that within benign prostatic hypertrophy, or non-cancerous prostate enlargement. The team showed the degrees of the activated Ack1 to be much higher in the advanced tumors. In earlier function, Earp’s UNC laboratory was the first ever to clone a cell surface tyrosine kinase, Mer. ‘We saw that Mer was expressed at reasonably high amounts in prostate malignancy cells.